ClinicalTrials.Veeva

Menu

Expanded Access to ANG1005 for Individual Patients

A

Angiochem

Status

Conditions

Leptomeningeal Carcinomatosis
Breast Cancer With Recurrent Brain Metastases
Anaplastic Oligodendroglioma
Anaplastic Astrocytoma

Treatments

Drug: ANG1005

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT02755987
ANG1005-EAP-01, EAP-02, EAP-03

Details and patient eligibility

About

This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Neurologically stable
  2. Karnofsky performance status (KPS) ≥ 80
  3. Adequate laboratory results

Exclusion criteria

  1. Radiotherapy within 3 months.
  2. Evidence of significant intracranial hemorrhage
  3. NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 Grade ≥ 2 neuropathy
  4. Inadequate bone marrow reserve
  5. Any evidence of severe or uncontrolled disease

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems